Clinical trials: SARS
COVID-19
Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)
This is a first in human, phase I, open-label, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in healthy adults.
- Trial name
- NCT05113849
- Testing
- IN-B009 (Low-dose), IN-B009 (High-dose)
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
SARS-CoV-2
Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 2)
Preliminarily explore the effect of oral probiotics in SARS-CoV-2 serum neutralizing antibody titer level and T cell response level (spot formation cell counting). Provide a reference for determining the appropriate oral regimen.
- Trial name
- NCT05195047
- Testing
- 1 week of probiotics(Week 1), 1 week of probiotics(Week 2)
- Where
- 2 sites in China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Peking University
Coronavirus
COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study
A phase I, experimental dose finding, open label, clinical infection, safety and viral detection optimisation in previously SARS-CoV-2 infected (unvaccinated or vaccinated) or uninfected vaccinated volunteers.
- Trial name
- NCT04864548
- Testing
- SARS-CoV-2 virus
- Where
- 3 sites in United Kingdom
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Oxford
SARS-CoV2 Infection, COVID-19 Testing
Generic Testing of Antigen Tests for COVID-19 in Denmark
To evaluate the analytical and clinical sensitivity and specificity of antigen tests performed as oropharyngeal swabs, outer nasal swabs, saliva swabs or breath tests including self-tests for SARS-CoV-2 towards standard RT-PCR…
- Trial name
- NCT04913116
- Testing
- Comparison of antigen tests with RT-PCR as reference method
- Where
- 3 sites in Denmark
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
SARS-CoV2 Infection
Cellular Senescence and COVID-19 Long-Hauler Syndrome
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
- Trial name
- NCT04903132
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Personal Protective Equipment, Self Contamination
Self-contamination Following Removal of Two Personal Protective Equipment Suits: a Crossover Trial
Anesthesiologists and other professionals are at high risk of viral infection during aerosol-generating procedures. Knowledge of the protective quality of PPE suits and the risk of self-contamination after removal is paramount.
- Trial name
- NCT04763304
- Testing
- Gown personal protective equipment (PPE-G) suit, Coverall personal protective equipment (PPE-C) suit
- Where
- Argentina
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Covid19
SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes
This study was designed to determine, in a screening situation within the framework of university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the staff of the University of Reims…
- Trial name
- SERUR (NCT04816084)
- Testing
- Anti-SARS-CoV2 Serology
- Where
- France
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Université de Reims Champagne-Ardenne
COVID-19
Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 in China
- Trial name
- NCT05682599
- Testing
- Azvudine
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
COVID-19, Myocarditis
Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance
Introduction: Coronavirus disease 2019 (COVID-19) remains a major health issue resulting in >800,000 deaths as of 30th August 2020. A concerning discovery of COVID-19 is the involvement of the myocardium.
- Trial name
- R-COVID-CMR (NCT05184114)
- Testing
- Cardiac Magnetic Resonance, Blood Tests
- Where
- Hong Kong
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
COVID 19
Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia
Descriptive prospective study to investigate the prevalence of COVID 19 during ambulant screening
- Trial name
- NCT04334252
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Jessa Hospital
SARS-CoV-2
Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )
This is a research study to evaluate the clinical utility of the Enhanced Preservation Media with Integrated Extraction (EPM-IX)
- Trial name
- CGI-EPM-IX (NCT05281692)
- Testing
- Enhanced Preservation Media (EPM-IX)
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Convergent Genomics, Inc.
COVID-19
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers
- Trial name
- NCT04870164
- Testing
- Ensovibep
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Molecular Partners AG
SARS-CoV-2 Infection
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)
An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a SARS-CoV-2 Omicron Challenge Strain (BA.5) in Healthy Participants 18 to 40 Years of Age
- Trial name
- NCT06492564
- Testing
- SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hvivo
COVID-19
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
To develop an effective vaccine against the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Clover Biopharmaceuticals is conducting a Phase 1 study (CLO-SCB-2019-001) in healthy volunteers to evaluate the…
- Trial name
- NCT04932824
- Testing
- SCB-2019
- Where
- Australia
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
BCG, COVID-19
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
In Mexico the total number of confirmed cases of COVID-19 is 232, 000 and 28,510 deaths. Health workers are at high risk of COVID-19 infection. Their absence from work dramatically limits the ability to contain the disease.
- Conditions
- BCG, COVID-19, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04461379
- Testing
- BCG vaccine
- Where
- Mexico
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
SARS-CoV-2
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid.
- Trial name
- CORVax12 (NCT04627675)
- Testing
- CORVax, IL-12 plasmid, Cliniporator
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Providence Health & Services
COVID-19
Dendritic Cell Vaccine to Prevent COVID-19
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04685603
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Indonesia-MoH
Covid19
Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19
In this phase I first-in-human clinical trial, healthy volunteers in two different dose cohorts will be vaccinated twice with the candidate vaccine MVA-SARS-2-S.
- Trial name
- NCT04569383
- Testing
- MVA-SARS-2-S vaccinations (days 0 & 28), Comirnaty
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
SARS (Disease)
Cyclosporine For The Treatment Of COVID-19(+)
Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no Neoral + SOC.
- Trial name
- NCT04492891
- Testing
- Cyclosporine, Standard of Care Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bryan Burt, MD
COVID-19
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years
This study is a randomized, double-blinded, and placebo-controlled phase Ib/IIb clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged ⩾60 Years.
- Trial name
- NCT04470609
- Testing
- Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
- Where
- China
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.